The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.
This is a disease registry, which is an organized system using non-interventional methods to collect data on a patient population defined by a particular disease, exposure, or condition, and which is followed over time. Non-interventional means that after participants enrollment, participants will be treated according to the routine clinical treatment decision by the physician. The registry will not impose any treatment or procedure for participants.
Study Type
OBSERVATIONAL
Enrollment
700
Holy Cross Health
Fort Lauderdale, Florida, United States
RECRUITINGThe Ohio State University Wexner Medical Center
Columbus, Ohio, United States
RECRUITINGVanderbilt University Medical Center
Nashville, Tennessee, United States
ACTIVE_NOT_RECRUITINGKlinikum Klagenfurt Am Woerthersee
Klagenfurt, Austria
RECRUITINGLandeskrankenhaus Salzburg - Universitätsklinikum der PMU
Salzburg, Austria
RECRUITINGKlinik Floridsdorf
Vienna, Austria
RECRUITINGJessa Ziekenhuis
Hasselt, Belgium
RECRUITINGAZ Delta
Roeselare, Belgium
RECRUITINGAZ Nikolaas
Sint-Niklaas, Belgium
RECRUITINGCliniques UCL de Mont-Godinne (7077)
Yvoir, Belgium
RECRUITING...and 69 more locations
Best Overall Response (BOR)
Time frame: Through study completion, up to approximately 4.9 years
Tumor Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1
Time frame: Up to approximately 4.9 years
Overall Survival (OS)
Time frame: Through study completion, up to approximately 4.9 years
Number of Participants with Adverse Events (AEs)
Time frame: Up to approximately 4.9 years
Number of Participants with Adverse Reactions (ARs)
Time frame: Up to approximately 4.9 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.